Aussies follow the US's lead in treating hard-to-reach patients

Direct-acting antivirals have been a game-changer in hepatitis C treatment, providing fresh hope for the 180,000 Australians estimated to be living with the chronic disease.


Despite the agents’ success — a cure rate above 95% — challenges remain in treating difficult-to-access populations such as IV drug users, people with psychiatric comorbidities and Indigenous Australians.

A novel approach to reach out to such patients, first developed in New Mexico, US, more than a decade ago, has recently been trialled in Sydney under the moniker